PITX1 and hepatocellular carcinoma: In our study, we also found that a high content of ccf-mtDNA was an independent prognostic factor for HBV-HCC patients receiving TACE combined with TCM treatment, suggesting its potential as a biomarker for identifying HCC patients who may benefit from this combination therapy.